Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.87.

  • Viridian Therapeutics, Inc.\DE's Equity Ratio fell 491.77% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 491.77%. This contributed to the annual value of 0.9 for FY2024, which is 37.46% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Equity Ratio is 0.87, which was down 491.77% from 0.88 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Ratio registered a high of 0.93 during Q3 2022, and its lowest value of 0.84 during Q2 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Equity Ratio value was 0.9 (recorded in 2024), while the average stood at 0.9.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Equity Ratio surged by 4431.62% in 2021 and then tumbled by 708.44% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Ratio (Quarter) stood at 0.92 in 2021, then decreased by 1.46% to 0.91 in 2022, then dropped by 0.74% to 0.9 in 2023, then grew by 0.37% to 0.9 in 2024, then decreased by 3.67% to 0.87 in 2025.
  • Its Equity Ratio was 0.87 in Q3 2025, compared to 0.88 in Q2 2025 and 0.91 in Q1 2025.